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 Abstract
Purpose: To evaluate the effects of mesenchymal stem cells on liver regeneration in rats 
following a 70% hepatectomy. 
Methods: Forty rats were subjected to 70% hepatectomy and then ~106 mesenchymal stem 
cells (test group), or saline solution (control group), were infused into their livers via the por-
tal vein. Each treatment group was divided into early and late subgroups (euthanized 3 d and 
5 d following the operation, respectively). Group comparisons of Albumin, aminotransamina-
ses (AST, ALT), and Alcaline Phosphatase (AP) levels, proliferative index (ki-67+ straining), and 
mitotic cell counts were conducted.
Results: No significant differences in liver regeneration rate, number of mitoses, proliferative 
index, or serum levels of albumin, AST, or AP were observed. ALT levels were higher in the test 
group than in the control group (p<.05).
Conclusions: Mesenchymal stem-cell therapy did not improve liver regeneration rate 3 d or 5 
d after 70% hepatectomy in rats. Likewise, the therapy appeared not to affect liver function, 
proliferative index, or number of mitoses significantly.
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and Tissue-Based Therapy. Rats.
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in experimental rat models involving a 70% 
hepatectomy followed by a stem cell transplant 
via the portal or peripheral veins, significant 
improvements in the rate of liver regeneration 
were observed, and this was accompanied by 
improvements in the Ki-67 index, in the mitotic 
index, and in real-time reverse transcriptase-
polymerase chain reaction (RT-PCR)  compared 
to the control groups10-12.
 While some studies have demonstrated 
that cell therapy can be beneficial following 
liver resection, a lack of standardization 
regarding the number of cells administered, 
the type of cell administered, and the grade 
of liver lesion treated have prevented a 
comparison and validation of cell therapy as 
a clinical application. Therefore, in this study, 
liver regeneration was evaluated in a rat model 
three days and five days after a 70% partial 
hepatectomy followed by a transplantation of 
mesenchymal stem cells through the portal 
vein. 
 ■ Methods
 The Ethics Committee of UNIFESP 
approved this study (CEP 0759/07) and both 
national and institutional protocols for the 
care and use of experimental animals were 
followed.
 Forty male Wistar rats (250–350g; 
n=40) were obtained from the Center for the 
Development of Experimental Models (Sao 
Paulo, Brazil). 
 Briefly, the animals underwent a 70% 
hepatectomy with bloc ligation of the left and 
right regions of the median lobes and the left 
lateral lobe. This was followed by an infusion 
of 106 mesenchymal stem cells (test group) or 
a PBS buffer solution (control group) through 
the portal vein. These two groups were then 
each subdivided into two groups to evaluate 
liver regeneration on the third day and on the 
fifth day following surgery, according with the 
 ■ Introduction
 Advances in the development and 
refinement of surgical techniques, combined 
with improvements in multidisciplinary 
therapy for oncological diseases, have led to 
indications for increasingly complicated liver 
resections. However, the mortality rates for 
patients undergoing these surgeries remain 
around 5%, even in referral centers. Post-
hepatectomy liver failure (PHLF) is the main 
cause of death for these patients, and mortality 
rates greater than 20% have been reported for 
PHLF patients with a history of chronic liver 
disease or cirrhosis1,2. A key risk factor that is 
associated with PHLF is small liver volume3. 
Therefore, portal vein embolization, portal 
vein ligation, two-stage hepatectomy, and 
ALPPS (Associating Liver Partition and Portal 
Ligation for Staged Hepatectomy) are a few 
of the strategies that have been developed to 
guarantee hypertrophy of the remaining liver 
tissue following surgery in order to prevent 
PHLF4,5.
 More recently, the potential for 
cell therapy to provide molecular and/or 
cellular stimuli to replace lesioned or lost 
tissues has been investigated, with the goal 
of restoring liver function6. To explore the 
mechanisms involved, the transdifferentiation 
of mesenchymal stem cells into hepatocytes, 
cell fusion experiments with formation of 
a hybrid hepatocytic, and investigations of 
paracrine and immunomodulatory effects 
have been performed7,8. In particular, an 
infusion of mesenchymal stem cell lysate, 
rather than whole cells, was found to improve 
liver regeneration. This effect was also 
accompanied by an improved biochemical 
profile and a reduction in cell apoptosis. Taken 
together, these results support the hypothesis 
that paracrine factors can improve the function 
of lesioned tissue by reducing inflammation 
and increasing vasculogenesis9. Furthermore, 
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scheme on the Figure 1. For these four groups, 
each total regenerated liver (TR) was resected 
and weighed.
Figure 1 - Demonstrative draft of the surgeries: A. 
First surgery showing the initial total liver (IT), the 
initial ressected liver (RL) and the liver remnant 
(Rem); B. The eutanasia surgery indicating the liver 
regeneration (LR), liver remnant (Rem) and total 
liver regenerated (TR).
Isolation and culturing of the mesenchymal 
stem cells
 Medulla ossea was collected from 
rats following a flush of the tibias and fibulas 
after anesthesia. After centrifugation, the 
resulting pellet was re-suspended in 4 mL of 
Dulbecco’s modified eagle medium (DMEM) 
and the mononuclear cells were separated 
using a Histopaque protocol (Sigma-Aldrich, 
St. Louis, MO, USA). The mononuclear cells 
were re-suspended in low-glucose DMEM 
supplemented with 10% fetal bovine serum 
(FBS, Gibco/Invitrogen) and were distributed in 
75 cm2 bottles (2 x 105 cells/bottle). The cells 
were maintained in a 5% CO2 incubator at 37°C 
for 10 to 15d. The cultures were maintained 
until their sixth passage.
Liver regeneration rate (LRR)
 The weight of the REMs were used to 
calculate the LRRs according to the following 
formula:
 
 
(TR  -  Rem ) 
Rem 
x  100 
 Rem   =   IT   x   0.7
TR   =   Rem   +   LR
LRR = liver regeneration rate
TR = total liver regenerated
Rem = liver remnant
IT = initial total liver
LR = liver regeneration
Analysis of the proliferative index and the 
number of mitoses events
 Histological slices of liver tissue were 
stained with eosin and hematoxylin, and then 
the number of hepatocytes present during 
mitosis were calculated. The slices were also 
incubated with an anti-Ki-67 antibody to 
calculate the positive: total Ki-67 hepatocyte 
ratio.
Biochemical analyses 
 Blood samples were collected from the 
retro-orbital plexus during surgery and at the 
time of euthanasia.  Following the separation 
of plasma for each of the samples, a standard 
method to measure alanine transaminase 
(ALT), alanine aminotransferase (AST), alkaline 
phosphatase (PA), and albumin levels was 
used.
Statistical analysis
 The Statistical Package for Social 
Sciences (SPSS v 18.0, Chicago, IL, USA) was used 
to perform statistical analyses. LRRs and the 
percentages of variation (delta) for the study 
variables were calculated. Student’s t-test was 
applied to the parametric variables (e.g., LRR, 
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delta albumin), while the Mann-Whitney test 
was applied to the non-parametric variables 
(e.g., delta ALT, AST, PA, Ki-67, and the number 
of mitosis events). The significance level was 
set at 0.05 or 5%.
 ■ Results
 There was no significant variation 
between any of the parameters examined, 
except for the TGP level which was significantly 
higher in the test group than in the control group 
(Tables 1 and 2). There were no differences 
between the test group and the control group 
regarding proliferative index values and the 
number of mitosis events (Tables 3 and 4). 
In addition, the LRRs for the control and test 
groups 3 and 5 days after surgery did not differ. 
For the former, the values for the test group 
and the control group were: 116.0 ± 28.6 (n = 
7) and 126.0 ± 24.1 (n = 9), respectively (p = 
0.490). For the latter, the values were: 159.8 
± 46.5 (n = 10) and 141.8 ± 22.7 (n = 10), 
respectively (p = 0.406).
Table 1 - Comparison of the variations in the levels of AF, AST, ALT, and albumin detected between 
the test and control groups on the third post-operative day.
Variation 
(∆)
3rd post-
op minus 
pre-op
control test
U p
N Mean SD Median Min Max N Mean SD Median Min Max
AF 7 92.4 66.2 82.7 21.9 200 9 44.8 36.9 39.9 -6.5 100 18 0.153
AST 6 20.6 24.6 22.3 -13.5 51.5 8 75.0 77.8 49.1 19.2 257.7 9 0.053
ALT 7 17.6 19.3 20 0 50 9 94.9 56.4 99.9 16.7 200.1 5 0.005*
Albumin 7 -19.5 6.0 -21.3 -29.2 -12 9 -17.9 10.3 -12.8 -38.9 -6.4 23 0.368
Post-op: post-operative day; Pre-op: pre-operative
Table 2 - Comparison of the variations in the levels of AF, AST, ALT, and albumin detected between 
the test and control groups on the fifth post-operative day.
Variation 
(∆)
5th 
post-op 
minus 
pre-op
control test
U p
N Mean SD Median Min Max N Mean SD Median Min Max
AF 10 44.9 32.4 43.0 13.5 120 10 35.80 24.8 36.6 -6.7 76 44 0.650
AST 10 48.8 54.5 40.6 -29.1 173.1 10 31.0 32.3 27.9 -12.9 81.5 40.5 0.473
ALT 10 6.4 51.9 17.0 -100 100 10 41.7 23.7 33.3 20 99.9 20 0.023*
Albumin 10 -19.5 8.7 -20.6 -30.2 -3.8 10 -16.9 7.05 -18.1 -28 -3.6 39 0.406
Post-op: post-operative day; Pre-op: pre-operative
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Table 3 - Evaluation of the proliferative index (Ki-67) and mitotic index for the test and control 
groups on the third post-operative day.
Variables
control test
U p
N Mean SD Median Min Max N Mean SD Median Min Max
Ki67 7 0.44 0.15 0.41 0.26 0.62 9 0.3 0.19 0.39 0.14 0.69 27 0.634
Mitotic 
Index 7 6.29 4.42 5.00 2.00 14.00 9 5.11 2.09 5.00 3.00 10.00 30 0.872
Table 4 - Evaluation of the proliferative index (Ki-67) and the mitotic index for the test and control 
groups on the fifth day following surgery and infusion.
Variables
control test
U p
N Mean SD Median Min Max N Mean SD Median Min Max
Ki67 10 0.10 0.08 0.0983 0.02 0.28 10 0.16 0.08 0.1412 0.05 0.28 30 0.131
Mitotic 
Index 10 1.00 0.67 1.00 0.00 2.00 10 0.60 0.52 1.00 0.00 1.00 34 0.165
 ■ Discussion
 For surgeries that include resection 
of a large portion of the liver, the residual 
volume of the liver is critical. Moreover, an 
increased risk of liver failure exists despite the 
high capacity for regeneration by this organ. 
This situation is even more acute for patients 
with a history of cirrhosis or chemotherapy13. 
A literature review with respect to chronic 
liver lesions identified eleven clinical trials that 
have investigated the effect of mesenchymal 
cells on the treatment of hepatic cirrhosis. 
However, the models of liver disease were 
quite different, and thus, a wide variation in the 
methodology and in the types of mesenchymal 
cells used was observed. Furthermore, none of 
these trials yielded strong scientific evidence14. 
Consequently, the benefits of liver resection 
remain to be confirmed, particularly regarding 
the therapeutic potential of a mesenchymal 
cell infusion for hepatic lesions. Improvements 
in liver tissue regeneration, either through 
transdifferentiation, cell fusion, release of 
trophic factors, or immunomodulation, also 
remain to be determined. 
 In the present study, it was examined 
whether an infusion of 106 stem cells following 
a 70% hepatectomy could lead to an increase in 
liver regeneration. When LRRs were compared 
for the test and control groups three and five 
days after each surgery and infusion were 
performed, no differences were detected. 
In addition, the rate of cell proliferation, the 
mitotic index values, and biochemical analyses 
showed no differences between the rats that 
received cell therapy and the control rats. In 
a literature search, only three studies were 
found to use mesenchymal stem cells in a 
similar hepactectomy model. In the model 
reported by Kanazawa et al.15 involving an 
ischemia method, the same administration 
route and cells that were used in the present 
method were applied, and an increase in the 
LRR was observed for the group that received 
the mesenchymal cell therapy. In the two other 
studies, both of the same authors, 3 x 107 and 
2 x 107 cells were transfused, respectively, and 
higher LRRs were also observed compared to 
the control groups10,11. However, in a report 
by Yu et al.16 when 5 x 106 mesenchymal stem 
cells were applied to an 85% hepatectomy 
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model, a higher LRR was not achieved in the 
mesenchymal cell group, but only in the group 
preconditioned with hypoxia. 
 The biochemical analyses performed in 
these studies yielded distinct and conflicting 
results. Furthermore, only one study previously 
calculated the proliferative index and the 
mitotic index to estimate improvements in 
liver regeneration11.
 Various factors may account for the 
differences in results between the present 
study and previous studies that evaluated 
liver regeneration. Initially, differences in the 
number of cells used are obvious. It would seem 
logical that the number of cells applied could 
be directly proportional to the magnitude of 
the observed effect. However, variations in the 
methods used to culture the cells in vitro, and 
the lack of specific surface markers to confirm 
each population of mesenchymal cells, makes 
it difficult to directly compare the studies. 
 Based on the conflicting results that 
have been reported, and the small number of 
comparable studies available, it is difficult to 
determine whether the present results confirm 
or negate a possible effect of mesenchymal 
stem cells on the rat model of acute liver lesion 
that was investigated. Moreover, there are 
various aspects that might serve as confounding 
factors in this evaluation. For example, there is 
the belief that the role played by mesenchymal 
cells can be measured in an animal model 
in which regeneration occurs with a low 
index of hepatic failure. Indeed, the normal 
mechanisms by which liver regeneration 
occurs could be enough itself to repair the 
liver lesion without the action of transplanted 
mesenchymal cells, thereby requiring that 
a stimuli of greater magnitude is needed, 
such as a 90% hepatectomy. Another point 
worthy of discussion is the imprecise nature of 
calculating liver regeneration. In the previous 
and in the present study, this calculation was 
based on an estimate of liver remnant weight 
based on the initial weight of the resected 
liver. Consequently, a wide variation in the 
percentage of mass resected was observed, 
and this may have led to a possibly bias in our 
results. Furthermore, the mesenchymal stem 
cell culture used represents a heterogeneous 
pool of cells, and the number of cells infused 
may or may not be responsible for the results 
observed. Correspondingly, the present results 
may be a characteristic of the infused cells and/
or the particles released by them.
 Cell therapy may have the potential 
to accelerate and/or stimulate tissue repair 
processes. Furthermore, mesenchymal cells 
represent a cell source that could provide 
sufficient numbers of cells to administer a graft 
treatment for patients that have undergone 
extensive liver resection to remove a lesion. 
However, certain issues need to be resolved 
before this therapy can be adopted into clinical 
practice. First, it needs to be demonstrated 
whether this therapy provides a real benefit. 
Then, the most effective cell clone needs to 
be identified, as well as the dose of cells to 
be infused, the number of infusions required, 
and the best means to achieve a successful cell 
transplant. Furthermore, a characterization of 
paracrine and immunomodulatory factors is 
needed to evaluate the viability of an allogeneic 
transplant. To pursue these goals, additional 
research is needed that involves larger sample 
sizes and validation of the model in other 
animals. However, the present findings support 
the pursuit of these additional investigations.
 ■ Conclusions
 Mesenchymal stem-cell therapy did 
not improve liver regeneration rate 3d or 5d 
after 70% hepatectomy in rats. Likewise, the 
therapy appeared not to affect liver function, 
proliferative index, or number of mitoses 
significantly.
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